Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC

Inclusion Criteria: * Males age ≥ 18 years； * Subjects who understand and sign the consent form for this study； * Metastatic， castrate resistant, histologically confirmed prostate cancer； * PSA\> 5ng / ml； * Serum testosterone ≤ 17nmol / L (50ng / dl)； * Expected survival time of at least 24 months； * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1； * Subjects did not receive chemotherapy, radiation therapy, surgery and other treatment within 4 weeks； Exclusion Criteria: * The subject has an allergic history of medicine or food； * The patient with more serious heart disease, including but not limited to myocardial infarction, cardiomyopathy, valvular disease, malignant arrhythmia； * Hb \<9.0 g / 100ml, WBC \<3 ×10\^9/ L, LY \<1.0 x10\^9/ L, platelet \<100,000 / mm3； * Patients with immune disease or auto-immune disease (such as Multiple sclerosis, systemic lupus erythematosus，rheumatoid arthritis and inflammatory bowel disease, vitiligo )； * The subject has uncontrolled or hard-to-control diseases of liver, or kidney system； * Patient with visceral metastases, pathological fractures, spinal cord compression symptoms； * Severe pain associated with bone metastases (VAS score ≧ 4 points)； * Patient has received immunotherapy (including but not limited to PD-1 / PDL-1, etc.)； * patient with irregular hemorrhagic disease； * Subject is HIV, hepatitis B virus, hepatitis C virus, Treponema pallidum infection； * Subject has uncontrollable seizures, or because of mental loss of self-knowledge and so on； * The subject has an history of other malignant tumor； * The patient had drug abuse, drug abuse, and long history of alcoholism in the 12 years prior to this trial； * The subject has participated in any other clinical trial in the 3 months prior to this trial； * The subject has any other unsuitable or adverse condition to be determined by the investigator.